Scribe Therapeutics Inc./$SCTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Scribe Therapeutics Inc.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
- Ticker
- $SCTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 82
- Headquarters
- Alameda, United States
- Website
- www.scribetx.com
SCTX Metrics
BasicAdvanced
$563M
-
-$13.18
-
-
Price and volume
Market cap
$563M
52-week high
$39.60
52-week low
$17.31
Average daily volume
206K
Financial strength
Current ratio
0.573
Quick ratio
0.562
Long term debt to equity
-0.092
Total debt to equity
-0.973
Interest coverage (TTM)
-14.83%
Profitability
EBITDA (TTM)
-27.82
Gross margin (TTM)
-53.28%
Net profit margin (TTM)
-97.00%
Operating margin (TTM)
-92.20%
Effective tax rate (TTM)
1.02%
Revenue per employee (TTM)
$410,000
Management effectiveness
Valuation
Price to book
-0.45
Price to tangible book (TTM)
-0.45
Free cash flow per share (TTM)
-15.59
Growth
What the Analysts think about SCTX
Analyst ratings (Buy, Hold, Sell) for Scribe Therapeutics Inc. stock.
Analyst projections of the future price of Scribe Therapeutics Inc. stock.
Bulls say / Bears say
SCTX achieved a major development milestone in May 2026 by receiving Australian regulatory clearance to begin the first-in-human STX-1150 study. The candidate is designed to epigenetically silence PCSK9 after a single dose without permanently altering DNA, potentially differentiating it from chronic lipid-lowering therapies. (Scribe Therapeutics)
The company received approximately $25.7 million in combined, non-dilutive CIRM grants for STX-1200 and STX-1400, supporting additional wholly owned programs targeting Lp(a) and triglycerides. This extends pipeline breadth while reducing near-term reliance on equity financing for those programs. (Scribe Therapeutics)
Recent preclinical data strengthened the STX-1150 thesis: a single administration of an ELXR prototype produced up to 68% LDL-C reduction in non-human primates, with reductions above 50% sustained for two years at a therapeutically relevant dose and liver-enzyme profiles comparable to saline controls. (Scribe Therapeutics)
SCTX remains pre-revenue and deeply loss-making: it reported a $23.8 million net loss for the first six months of 2026, versus $13.3 million a year earlier, with an accumulated deficit of $181.5 million. The company will likely require additional capital before commercialization, creating future dilution risk. (SEC)
STX-1150 has only recently entered Phase 1, and the company does not expect initial human safety, tolerability, or LDL-C data until the first half of 2027. The investment case therefore remains heavily dependent on unproven translation from preclinical results to human efficacy and safety. (Scribe Therapeutics)
The platform carries substantial execution and manufacturing risk: Scribe states that its manufacturing evidence is preliminary and has not yet been demonstrated at scale, while failures by third-party manufacturers or CROs could delay trials or prevent commercialization. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
SCTX Financial Performance
Revenues and expenses
SCTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.